354 related articles for article (PubMed ID: 28673522)
1. Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.
Hui D; Weinstein ZM; Cheng DM; Quinn E; Kim H; Labelle C; Samet JH
J Subst Abuse Treat; 2017 Aug; 79():12-19. PubMed ID: 28673522
[TBL] [Abstract][Full Text] [Related]
2. Long-term retention in Office Based Opioid Treatment with buprenorphine.
Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
[TBL] [Abstract][Full Text] [Related]
3. Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine.
Weinstein ZM; Cheng DM; Quinn E; Hui D; Kim H; Gryczynski G; Samet JH
Drug Alcohol Depend; 2017 Jan; 170():9-16. PubMed ID: 27865152
[TBL] [Abstract][Full Text] [Related]
4. Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study.
Geist ML; Radick AC; Tsui JI; Blalock KL; Adwell A; Tamru E; Connolly NC; James JR
Addict Sci Clin Pract; 2023 May; 18(1):33. PubMed ID: 37231486
[TBL] [Abstract][Full Text] [Related]
5. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine.
Du CX; Shi J; Tetrault JM; Madden LM; Barry DT
Fam Pract; 2022 Mar; 39(2):234-240. PubMed ID: 34893825
[TBL] [Abstract][Full Text] [Related]
6. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
[No Abstract] [Full Text] [Related]
7. Staff Attitudes toward Buprenorphine before and after Implementation of an Office-Based Opioid Treatment Program in an Urban Teaching Clinic.
James JR; Marolf M; Klein JW; Blalock KL; Merrill JO; Tsui JI
Subst Use Misuse; 2021; 56(11):1569-1575. PubMed ID: 34282999
[TBL] [Abstract][Full Text] [Related]
8. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.
LaBelle CT; Han SC; Bergeron A; Samet JH
J Subst Abuse Treat; 2016 Jan; 60():6-13. PubMed ID: 26233698
[TBL] [Abstract][Full Text] [Related]
9. Training in office-based opioid treatment with buprenorphine in US residency programs: A national survey of residency program directors.
Tesema L; Marshall J; Hathaway R; Pham C; Clarke C; Bergeron G; Yeh J; Soliman M; McCormick D
Subst Abus; 2018; 39(4):434-440. PubMed ID: 29513136
[TBL] [Abstract][Full Text] [Related]
10. Common elements in opioid use disorder guidelines for buprenorphine prescribing.
Atkinson TJ; Pisansky AJB; Miller KL; Yong RJ
Am J Manag Care; 2019 Mar; 25(3):e88-e97. PubMed ID: 30875177
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders.
Carey KJ; Huang W; Linas BP; Tsui JI
J Subst Abuse Treat; 2016 Jul; 66():54-9. PubMed ID: 26988423
[TBL] [Abstract][Full Text] [Related]
12. Three-year Retention Rates With Office-based Treatment of Buprenorphine for Opioid Use Disorder in a Private Family Medicine Practice.
Cope K; DeMicco J; Salib J; Michael M; Yakoub P; Daoud K; Cope R
J Addict Med; 2022 Nov-Dec 01; 16(6):716-721. PubMed ID: 35913992
[TBL] [Abstract][Full Text] [Related]
13. Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program.
Weinstein ZM; Gryczynski G; Cheng DM; Quinn E; Hui D; Kim HW; Labelle C; Samet JH
Drug Alcohol Depend; 2018 Aug; 189():166-171. PubMed ID: 29958128
[TBL] [Abstract][Full Text] [Related]
14. Hospitalized opioid-dependent patients: Exploring predictors of buprenorphine treatment entry and retention after discharge.
Lee CS; Liebschutz JM; Anderson BJ; Stein MD
Am J Addict; 2017 Oct; 26(7):667-672. PubMed ID: 28324627
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of a novel office-based opioid treatment program in an internal medicine resident continuity practice.
Pytell JD; Buresh ME; Graddy R
Addict Sci Clin Pract; 2019 Dec; 14(1):46. PubMed ID: 31856915
[TBL] [Abstract][Full Text] [Related]
16. Patient Perceptions of Integrating Meditation-based Interventions in Office-based Opioid Treatment with Buprenorphine: A Mixed-methods Survey.
Tofighi B; Marini C; Lee JD; Garland EL
J Addict Med; 2023 Sep-Oct 01; 17(5):517-520. PubMed ID: 37788602
[TBL] [Abstract][Full Text] [Related]
17. Financial sustainability of payment models for office-based opioid treatment in outpatient clinics.
Hodgkin D; Horgan C; Bart G
Addict Sci Clin Pract; 2021 Jul; 16(1):45. PubMed ID: 34225785
[TBL] [Abstract][Full Text] [Related]
18. "I'm on the Right Path": Exploring 1-Month Retention in a Homeless-Tailored Outpatient-Based Opioid Treatment Program.
Fine DR; Critchley N; Hart K; Joyce A; Sporn N; Gaeta J; Wright J; Baggett TP; Kruse G
Subst Use Addctn J; 2024 Apr; 45(2):268-277. PubMed ID: 38258838
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio.
Accurso AJ; Lee JD; McNeely J
J Subst Abuse Treat; 2017 Dec; 83():62-67. PubMed ID: 29129197
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective.
Choi SA; Yan CH; Gastala NM; Touchette DR; Stranges PM
J Subst Use Addict Treat; 2024 May; 160():209237. PubMed ID: 38061629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
